



November 6, 2013

## **Integra LifeSciences Prices Public Offering of Common Stock**

PLAINSBORO, N.J., Nov. 6, 2013 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced that it has priced its previously announced underwritten public offering of 3,500,000 shares of its common stock at \$40.00 per share. In connection with the offering, Integra has also granted the underwriters a 30-day option to purchase an additional 525,000 shares of common stock. The offering is expected to close on November 13, 2013, subject to customary closing conditions.

Integra intends to use the net proceeds from the offering, including any net proceeds received from an exercise of the underwriters' option to purchase additional shares, for general corporate purposes which may include reducing outstanding borrowings under Integra's senior credit facility and paying a portion of the purchase price for the proposed acquisition by Integra LifeSciences Corporation, Integra's wholly-owned subsidiary, of Confluent Surgical, Inc., including its DuraSeal™ product line.

The shares will be issued pursuant to an effective shelf registration statement on Form S-3. Before investing in the offering, interested parties should read the prospectus and related prospectus supplement for this offering and the other documents Integra has filed with the Securities and Exchange Commission.

Morgan Stanley, BofA Merrill Lynch, Wells Fargo Securities and RBC Capital Markets are acting as joint book-running managers for the offering. HSBC, Mitsubishi UFJ Securities, RBS, Barclays, Oppenheimer & Co. and SunTrust Robinson Humphrey are acting as co-managers for the offering. The offering is being made by means of a prospectus and related prospectus supplement, copies of which may be obtained, when available, from Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, by calling (866) 718-1649, or by emailing [prospectus@morganstanley.com](mailto:prospectus@morganstanley.com), from BofA Merrill Lynch, Attention: Prospectus Department, 222 Broadway, New York, NY 10038, or by emailing [dg.prospectus\\_requests@baml.com](mailto:dg.prospectus_requests@baml.com), from Wells Fargo Securities, LLC, 1525 West W.T. Harris Boulevard, NC0675, Charlotte, NC 28262, Attention: Capital Markets Client Support, by calling (800) 326-5897 or by emailing [cmclientsupport@wellsfargo.com](mailto:cmclientsupport@wellsfargo.com) or from RBC Capital Markets, Attention: Equity Syndicate, Three World Financial Center, 200 Vesey Street, 8th Floor, New York, NY 10281 or by calling (877) 822-4089. Electronic copies of the prospectus and related prospectus supplement may be obtained by visiting EDGAR on the SEC's website at <http://www.sec.gov>.

This press release does not and shall not constitute an offer to sell or the solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any state or any jurisdiction. Any offer, if at all, will be made only by means of a prospectus and related prospectus supplement forming a part of the effective shelf registration statement.

### **About Integra**

Integra LifeSciences, a world leader in medical technology, is dedicated to limiting uncertainty for surgeons, so they can concentrate on providing the best patient care. Integra offers innovative solutions in orthopedic extremity surgery, neurosurgery, spine surgery, and reconstructive and general surgery.

### **Forward-Looking Statements**

*This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and reflect Integra's judgment as of the date of this release. Forward-looking statements include, but are not limited to, the expectations, plans and prospects for Integra, including whether or not Integra will offer the securities or consummate the offering, the anticipated terms of the offering and the anticipated use of proceeds of the offering. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. These risks and uncertainties include market conditions and other factors beyond Integra's control and the economic, competitive, governmental, technological and other factors identified under the heading "Risk Factors" included in Item 1A of Integra's Annual Report on Form 10-K for the year ended December 31, 2012 and information contained in subsequent filings with the Securities and Exchange Commission. These forward-looking statements are made only as of the date hereof, and Integra undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.*

CONTACT: Integra LifeSciences Holdings Corporation

John B. Henneman, III

Corporate Vice President

Finance and Administration

& Chief Financial Officer

(609) 275-0500

Investor Relations:

Angela Steinway

(609) 936-2268

[angela.steinway@integralife.com](mailto:angela.steinway@integralife.com)